Background. Carboplatin is an analogue of cisplatin with less nonhematologic toxicity than
A Phase II study of carboplatin as a treatment for children with acute leukemia recurring in bone marrow : A report of the Children's Cancer Group
โ Scribed by Lawrence J. Ettinger; Percy Ivy; Paul S. Gaynon; Alice G. Ettinger; Wen Liu-Mares; Mark D. Krailo
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 79 KB
- Volume
- 80
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
BACKGROUND.
Carboplatin is an analogue of cisplatin with less nonhematologic toxicity
๐ SIMILAR VOLUMES
Background. Maintenance of second remission of childhood acute lymphoblastic leukemia (ALL) with intensive chemotherapy is often unsuccessful. The major cause of treatment failure is relapse. Materials and Methods. Of 96 children with ALL who relapsed in the marrow while on or within 1 year of comp
## Background: The authors have determined the prognostic significance of cytogenetically detectable 12p abnormalities, which are frequent in children with acute lymphoblastic leukemia (all), in a large cohort of patients treated on risk-adjusted protocols of the children's cancer group (ccg). ##
## Background: This phase i trial was developed to determine the safety, biologic activity, and effects on hematopoietic recovery of pixy321 following ifosfamide, carboplatin, and etoposide chemotherapy for children with recurrent or refractory solid tumors. ## Methods: Children (age < 22 years a
## BACKGROUND. Children with Philadelphia (Ph) chromosome positive ( ฯฉ ) acute lymphoblastic leukemia (ALL) represent a subgroup at very high risk for treatment failure. In this report, the authors assessed the outcome of Ph ฯฉ ALL in a large cohort of children treated on contemporary intensive che